As several studies indicated that GSK-3β is one of the targets of luteolin in several types of cancers30,31, we next investigated whether FZD6-mediated inhibitory effect of luteolin is GSK-3β-independent in prostate cancer. This evidence concerns the gene GSK3B and prostate cancer.